Labcorp (LH)

Health Care · $30.2B market cap · SEC CIK 0000920148

Next reports on Feb 15, 2027, with analysts expecting $4.65 in earnings per share.

52-week range $244.52 to $373.76. 1% below its 52-week high and 52% above its low.

The case for LH

• Pays a modest 1.4% dividend.
• Within 1% of its 52-week high: the trend is up.
• Up 47.1% over the past year.

The case against

• Expensive for its growth: 30.1× earnings, where 0% a year of growth plus a 1.4% dividend would justify about 10×.
• Growth is weak (26/100): revenue +6.0%, EPS +19.7%, 0.0% a year over five years.
• Long-term debt of $5.1B against $532M of cash.

What the score is made of

Each factor is half a curve over reported figures and half a rank among the other Health Care companies (momentum is judged against fixed thresholds only), and the five are blended by weight. The score is where that blend places it in the S&P 500. It describes the last filing and the current price. It is not a forecast.

• Each factor except momentum is half fixed thresholds, half rank among the 59 Health Care companies.

The financials

The financials, five years deep

Pulled from Labcorp's XBRL filings on SEC EDGAR. Italic rows are worked out from the others.

What Labcorp says it does

Labcorp ® Holdings Inc. is a global leader of innovative and comprehensive laboratory services that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. The Company provides insights and accelerates innovations to improve health and improve lives through its unparalleled diagnostics and drug development laboratory capabilities. During 2025, the Company’s nearly 71,000 employees served clients in approximately 100 countries and performed more than 750 million tests for patients around the world. In addition, the Company provided support for more than 85% of the new drugs and therapeutic products approved in 2025 by the FDA. The Company’s strength in science, technology, and innovation, as well as its global scale, powers its continued success, differentiates the Company, and enables it to play a leading role in advancing healthcare across the…

Risk factors LH lists in its 10-K

• General or macro-economic factors and significant fluctuations in economic conditions in the U.S. and globally may have a material adverse effect on the Company
• An inability to attract, retain, and develop experienced and qualified personnel, including personnel in key roles and critical positions, and increased personnel costs, could adversely affect the Company’s business
• Changes in government regulation or in practices relating to the pharmaceutical, biotechnology, or medical device industries could decrease the need for certain services that BLS provides
• Increased competition, including price competition, could have an adverse effect on the Company’s revenues and profitability
• Failure to develop or acquire licenses for new or improved testing technologies, or the Company’s customers using new technologies to replace offerings currently provided by the Company could adversely affect its business
• Changes or disruption in services, supplies, or transportation provided by third parties have impacted, and could in the future materially impact, the Company’s operations and business
• A failure to identify suitable acquisition targets and successfully close and integrate acquisitions could have a material adverse effect on the Company’s business objectives and its revenues and profitability
• Continued and increased consolidation of pharmaceutical, biotechnology and medical device companies, health systems, physicians and other customers could adversely affect the Company’s business
• Damage or disruption to the Company’s facilities or operations therein could adversely affect the Company’s business
• The failure to establish, update, or perform to appropriate quality standards could adversely affect the Company’s business and reputation
• The Company bears financial risk for contracts that, including for reasons beyond the Company’s control, may be underpriced, subject to cost overruns, delayed, or terminated or reduced in scope
• A significant increase in the Company’s days sales outstanding could have an adverse effect on the Company’s business, including by increasing its bad debt or decreasing its cash flow
• BLS’s revenues depend on R&D spending by companies in the pharmaceutical, biotechnology and medical device industries
• Foreign currency exchange fluctuations could have an adverse effect on the Company’s business
• The Company’s level of indebtedness and debt service requirements could adversely affect the Company’s liquidity, results of operations, and business
• The Company’s quarterly results of operations may vary significantly from quarter to quarter making it harder to predict future results
• The Company might not be able to engage in certain desirable capital raising or strategic transactions as a result of the Spin-off and may not achieve its intended results
• Cybersecurity incidents and unauthorized access to the Company's or its customers’ data could harm the Company’s reputation and adversely affect its business
• The use of AI and machine learning tools in the Company’s operations and the services of third-parties may introduce risks that could adversely affect the Company’s business, financial condition, and reputation
• Changes in payer regulations or policies, insurance regulations or approvals, or changes in laws, regulations, or policies in the U.S. or globally, including changes in their interpretation, may adversely affect the Company
• The Company could face significant monetary damages and penalties and/or exclusion from government programs if it violates anti-fraud and abuse laws
• The Company’s international operations could subject it to additional risks and expenses that could adversely impact the business or results of operations
• International operations may increase the Company’s exposure to liabilities under applicable anti-corruption laws
• Increased regulations and restrictions on the import of research animals, limitations of supply of research animals, and actions of animal rights activists may have an adverse effect on the operations of BLS or the Company
• Animal populations may suffer diseases that can damage BLS’s inventory, harm its reputation, or result in other liability
• Failure to conduct animal research in compliance with animal welfare laws and regulations could result in sanctions and/or remedies against BLS and have a material adverse effect on the Company
• U.S. FDA regulation of LDTs and regulation by other countries of diagnostic offerings could have a material adverse effect on the Company’s business
• Views on matters relating to corporate responsibility and governance and the perception of the Company’s activities in these areas by stakeholders may impact the Company’s business and reputation
• Adverse results in material litigation matters could have a material adverse effect on the Company’s business
• The failure to successfully obtain, maintain, and enforce intellectual property rights and defend against challenges to the Company’s intellectual property rights could adversely affect the Company
• Changes in tax laws and regulations or the interpretation of such may have a significant impact on the financial position, results of operations, and cash flows of the Company
• Contract services in the drug development industry create liability risks

Filings

Other Health Care companies